Ovid Therapeutics (OVID) News Today $0.55 +0.07 (+14.75%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.56 +0.01 (+1.09%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock OVID Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Ovid Therapeutics management to meet with B. RileyJuly 17 at 5:35 AM | msn.comOvid Therapeutics Approves Key Proposals at Annual MeetingJuly 10, 2025 | tipranks.comOvid Therapeutics Inc. (OVID) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comOvid Therapeutics Inc Chart - MorningstarJuly 2, 2025 | morningstar.comMOvid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market - NasdaqJune 27, 2025 | nasdaq.comOvid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million - NasdaqJune 27, 2025 | nasdaq.comOvid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesJune 25, 2025 | finanznachrichten.deOvid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 MillionJune 25, 2025 | quiverquant.comQOvid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesJune 25, 2025 | globenewswire.comAre These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?June 20, 2025 | msn.comOvid Therapeutics Inc. to Host Event on Biomarkers in Epilepsy featuring Dr. Alexander RotenbergJune 5, 2025 | quiverquant.comQOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comOvid Police Chief, city accused of civil rights violationsApril 24, 2025 | msn.comOvid Therapeutics (OVID) Receives a Buy from TD CowenApril 23, 2025 | theglobeandmail.comOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $2 from $3 at H.C. WainwrightMarch 25, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $4 from $5 at BTIGMarch 25, 2025 | markets.businessinsider.comOvid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 12, 2025 | finance.yahoo.comWilliam Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)March 12, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $3 from $4 at WedbushMarch 12, 2025 | markets.businessinsider.comWe're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn RateMarch 11, 2025 | uk.finance.yahoo.comOvid Therapeutics sees cash runway into 2H26March 11, 2025 | markets.businessinsider.comOvid Therapeutics reports Q4 EPS (13c), consensus (17c)March 11, 2025 | markets.businessinsider.comOvid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comOvid Therapeutics appoints new board member and updates compensation policyMarch 7, 2025 | investing.comOvid Therapeutics appoints Papadopoulos to board of directorsMarch 4, 2025 | markets.businessinsider.comOvid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of DirectorsMarch 3, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Vertex Pharmaceuticals (VRTX) and Viridian Therapeutics (VRDN)February 27, 2025 | markets.businessinsider.comOvid Therapeutics to Present at the TD Cowen 45th Annual Health Care ConferenceFebruary 27, 2025 | globenewswire.comOvid Therapeutics faces Nasdaq delisting over share priceFebruary 13, 2025 | msn.comOvid stock plunges to 52-week low, touches $0.59 amid downturnFebruary 12, 2025 | msn.comOvid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comOvid Therapeutics stock hits 52-week low at $0.68 amid downturnJanuary 31, 2025 | msn.comOppenheimer raises Ovid stock rating, sets $4 price targetJanuary 31, 2025 | msn.comOvid therapeutics president and COO acquires $4,971 in stockJanuary 30, 2025 | msn.comOvid Therapeutics upgraded to Outperform from Perform at OppenheimerJanuary 30, 2025 | markets.businessinsider.comOvid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’January 30, 2025 | markets.businessinsider.comOppenheimer Upgrades Ovid Therapeutics (OVID)January 30, 2025 | msn.comOppenheimer Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Outperform"January 29, 2025 | marketbeat.comOvid Therapeutics Insider Ups Holding During YearJanuary 23, 2025 | finance.yahoo.comShort Interest in Ovid Therapeutics Inc. (NASDAQ:OVID) Decreases By 27.0%January 15, 2025 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of "Moderate Buy" by AnalystsJanuary 12, 2025 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Sees Significant Growth in Short InterestDecember 31, 2024 | marketbeat.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by BrokeragesDecember 18, 2024 | marketbeat.comBiohaven Ltd.’s Promising Pipeline and Strategic Partnerships Drive Buy RecommendationDecember 17, 2024 | markets.businessinsider.comConvergent Therapeutics Appoints Barbara Duncan to Board of DirectorsDecember 11, 2024 | finance.yahoo.comOvid Therapeutics’ OV329: Promising Safety and Efficacy Lead to Buy RatingDecember 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Ovid Therapeutics (OVID)December 9, 2024 | markets.businessinsider.comHC Wainwright Has Positive Outlook of OVID FY2024 EarningsDecember 6, 2024 | marketbeat.comOvid Therapeutics’ KCC2 Activators Show Promise for Excitability Disorders: Analyst Recommends Buy with $3 Price TargetDecember 5, 2024 | markets.businessinsider.com Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address OVID Media Mentions By Week OVID Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OVID News Sentiment▼-0.740.57▲Average Medical News Sentiment OVID News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OVID Articles This Week▼12▲OVID Articles Average Week Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IOBT News CHRS News CRDL News HLVX News TCRX News SAVA News ANIX News COYA News CRBP News HURA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OVID) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OVID Stock Alerts